BCR and hematopoietic and lymphoid cell neoplasm: Although the breakpoints for BCR fusion proteins in hematologic cancers vary, they all contain the coiled-coil dimerization domain present in BCR (Figure 3), indicating that the dimerization domain is vital for the oncogenic ability of these fusions.